Psychological Medicine: Volume 53 -

PRINCE Secondary: transdiagnostic CBT is not effective for persistent physical symptoms
Michiel Tack, David M. Tuller
Published online by Cambridge University Press:

17 August 2021, pp. 3230-3231
- Article
- - You have access
- PDF
- HTML
- Export citation

Response to the commentary by Bankart and Brugha
Yi-Ling Chien
Published online by Cambridge University Press:

27 December 2021, pp. 3773-3774
- Article
- - You have access
- PDF
- HTML
- Export citation

PSM volume 53 issue 14 Cover and Front matter
Published online by Cambridge University Press:

26 October 2023, pp. f1-f2
- Article
- - You have access
- PDF
- Export citation

The elusive search for a biomarker of dissociative amnesia: an overstated response to understated findings? – CORRIGENDUM
Antje A.T.S. Reinders, Lora I. Dimitrova, Yolanda R. Schlumpf, Eline M. Vissia, Sophie L. Dean, Lutz Jäncke, Sima Chalavi, Dick J. Veltman, Ellert R.S. Nijenhuis
Published online by Cambridge University Press:

01 February 2023, pp. 2713-2719
- Article
- - You have access
- PDF
- HTML
- Export citation

The MooDFooD randomized controlled trial: the data and its implications for the theory
Florian Thomas-Odenthal, Patricio Molero, Marc Molendijk
Published online by Cambridge University Press:

27 April 2023, pp. 5882-5883
- Article
- - You have access
- PDF
- HTML
- Export citation

The fundamental questions left unanswered: response to commentary on the ‘problems with delay discounting’
Allen J. Bailey, Ricardo J. Romeu, Peter R. Finn
Published online by Cambridge University Press:

04 February 2022, pp. 1660-1661
- Article
- - You have access
- PDF
- HTML
- Export citation

The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review
Chad A. Bousman, Abdullah Al Maruf, Diogo Ferri Marques, Lisa C. Brown, Daniel J. Müller
Published online by Cambridge University Press:

29 September 2023, pp. 7983-7993
- Article
- - You have access
  - Open access
- PDF
- HTML
- Export citation
Psychotropic medication efficacy and tolerability are critical treatment issues faced by individuals with psychiatric disorders and their healthcare providers. For some people, it can take months to years of a trial-and-error process to identify a medication with the ideal efficacy and tolerability profile. Current strategies (e.g. clinical practice guidelines, treatment algorithms) for addressing this issue can be useful at the population level, but often fall short at the individual level. This is, in part, attributed to interindividual variation in genes that are involved in pharmacokinetic (i.e. absorption, distribution, metabolism, elimination) and pharmacodynamic (e.g. receptors, signaling pathways) processes that in large part, determine whether a medication will be efficacious or tolerable. A precision prescribing strategy know as pharmacogenomics (PGx) assesses these genomic variations, and uses it to inform selection and dosing of certain psychotropic medications. In this review, we describe the path that led to the emergence of PGx in psychiatry, the current evidence base and implementation status of PGx in the psychiatric clinic, and finally, the future growth potential of precision psychiatry via the convergence of the PGx-guided strategy with emerging technologies and approaches (i.e. pharmacoepigenomics, pharmacomicrobiomics, pharmacotranscriptomics, pharmacoproteomics, pharmacometabolomics) to personalize treatment of psychiatric disorders.